Drug Type Small molecule drug |
Synonyms 3,7-dihydro-3,7-dimethyl-1H-purine-2,6-dione, 3,7-dimethylpurine-2,6-dione, 3,7-dimethylxanthine + [2] |
Target |
Mechanism A1R antagonists(Adenosine A1 receptor antagonists), A2aR antagonists(Adenosine A2a receptor antagonists), PDE4B inhibitors(Phosphodiesterase 4B inhibitors) |
Therapeutic Areas |
Active Indication |
Inactive Indication- |
Originator Organization |
Active Organization |
Inactive Organization- |
Drug Highest PhaseApproved |
First Approval Date- |
Regulation- |
Molecular FormulaC7H8N4O2 |
InChIKeyYAPQBXQYLJRXSA-UHFFFAOYSA-N |
CAS Registry83-67-0 |
Start Date19 Jan 2022 |
Sponsor / Collaborator |
Start Date01 Jul 2012 |
Sponsor / Collaborator |
Start Date17 May 2012 |
Sponsor / Collaborator |
KEGG | Wiki | ATC | Drug Bank |
---|---|---|---|
- | Theobromin |
Indication | Country/Location | Organization | Date |
---|---|---|---|
Cardiovascular Diseases | CN | - |
Study | Phase | Population | Analyzed Enrollment | Group | Results | Evaluation | Publication Date |
---|
No Data |